Policy aims to counter import dumping, enhance supply-chain security, and accelerate API self-reliance

The Union Government has introduced a minimum import price (MIP) on select pharmaceutical raw materials. The move is intended to curb the influx of underpriced imports—primarily from China—and provide domestic manufacturers with a more competitive and sustainable operating environment.

The regulated ingredients form part of the government’s Production Linked Incentive (PLI) scheme for pharmaceuticals, which seeks to reduce India’s heavy dependence on imported active pharmaceutical ingredients (APIs) and critical intermediates used in antibiotics and cardiovascular drugs. By setting a price floor for imports, policymakers aim to prevent predatory pricing practices that have historically undermined local production capacity.

Balancing Affordability with Supply Security

While the introduction of an MIP could lead to marginal increases in input costs, potentially impacting short-term drug pricing, industry experts view the policy as a long-term strategic investment. A stronger domestic API ecosystem is expected to enhance supply security, reduce vulnerability to global disruptions, and support India’s broader self-reliance agenda in pharmaceuticals.

For healthcare providers and payers, the policy underscores a trade-off between immediate cost pressures and long-term system resilience. Ensuring uninterrupted access to essential medicines—particularly antibiotics and chronic-care drugs remains a critical priority.

Quality Compliance Emerges as a Central Challenge

The policy places increased responsibility on domestic manufacturers to scale up production without compromising quality. Concerns persist over the industry’s compliance track record, especially among small and medium enterprises (SMEs), where lapses in manufacturing standards have previously led to regulatory action and, in some cases, patient safety incidents.

The challenge is further compounded by the implementation of the revised Schedule M guidelines, which mandate stricter Good Manufacturing Practices (GMP). Many registered SME units face the risk of closure if they fail to comply by the December 31 deadline, prompting industry bodies to seek deadline extensions.

Industry Accountability and Government Support Go Hand in Hand

As India tightens regulatory oversight, industry associations are expected to play a proactive role in supporting SMEs, both in accessing PLI benefits and in upgrading quality systems. Experts caution that cost pressures should not drive smaller units toward shortcuts that could weaken compliance and undermine trust in India’s pharmaceutical exports.

For the government, the current moment calls for a calibrated approach that combines regulatory firmness with targeted handholding. Financial support, technical assistance, and faster approvals could help manufacturers transition to higher standards while preserving production continuity.

Also read: Thyrocare Appoints Dr. Ramesh Kinha as Chief Operating Officer

Implications for the Healthcare Ecosystem

For healthcare stakeholders, including drug manufacturers, procurement leaders, insurers, and hospital networks, the minimum import price policy signals a decisive move toward supply-chain resilience and domestic value creation. Its success, however, will depend on how effectively the industry aligns cost competitiveness with quality excellence.

As India positions itself as a global pharmaceutical manufacturing hub, the convergence of pricing safeguards, incentive-linked production, and stricter compliance frameworks could define the sector’s credibility and sustainability in the years ahead.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!